Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 2/20 | 0.34 |
| ▸ | QRFPR | Q96P65 | 1/20 | 0.33 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | HTR6 | P50406 | 1/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.33 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.32 |
| ▸ | ELANE | P08246 | 1/20 | 0.32 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.31 |
| ▸ | FEN1 | P39748 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20102573 | 0.92 | RIPK1 (0.32) | RIPK1HTR2AHTR2CHTR2B | |
| SCHEMBL20102515 | 0.89 | RIPK1 (0.35) | PTGER1RIPK1HPGDHTR2AHTR2C | |
| SCHEMBL20111289 | 0.89 | SLC6A4 (0.35) | CYP19A1PTGER1PDK2SLC6A4HTR6 | |
| SCHEMBL20111248 | 0.88 | QRFPR (0.36) | QRFPRHPGD | |
| SCHEMBL20102526 | 0.86 | CYP19A1 (0.33) | CYP19A1SLC6A4HTR6C5AR1ELANE | |
| SCHEMBL20111710 | 0.85 | HPGD (0.33) | QRFPRHPGD | |
| SCHEMBL20111342 | 0.85 | ALOX5AP (0.39) | PTGER1PDK2SLC6A4HTR6ALOX5AP | |
| SCHEMBL20102516 | 0.85 | RIPK1 (0.33) | RIPK1HTR2AHTR2CHTR2B | |
| SCHEMBL20111478 | 0.84 | HPGD (0.34) | SLC6A4HTR6RIPK1HPGDHTR2A | |
| SCHEMBL20102519 | 0.83 | HTR2A (0.34) | PTGER1RIPK1HPGDHTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10323187-B2 | Liquid crystal compound having biphenylene, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2019-06-18 | — | — | US | disclosed |
| US-20180119009-A1 | LIQUID CRYSTAL COMPOUND HAVING BIPHENYLENE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180119009-A1 | LIQUID CRYSTAL COMPOUND HAVING BIPHENYLENE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | YBX1, PIEZO1, C1S | CYP19A1 671/4885QRFPR 2307/4885PTGER1 1465/4885 |
| US-10323187-B2 | Liquid crystal compound having biphenylene, liquid crystal composition and liquid crystal display device | YBX1, PIEZO1, C1S | CYP19A1 671/4885QRFPR 2307/4885PTGER1 1465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.